Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02405260 · ClinicalTrials.gov registry record · Phase 2
Add Glucokinase Activator to Target A1c
A Phase 2 study of Diabetes Mellitus, Type 2, sponsored by vTv Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 190
- Enrollment target
- 20
- Study locations
NCT02405260 is a Phase 2 study of Diabetes Mellitus, Type 2 that has completed, run by vTv Therapeutics. The registered enrollment target is 190 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT02405260, a Phase 2 study of Diabetes Mellitus, Type 2, has completed, sponsored by vTv Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 190 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is a multi-center, adaptive, randomized, double-blind, placebo- and active- controlled, parallel group, Phase 2 study in subjects with T2DM to evaluate the effect of TTP399 on HbA1c following administration for 6 months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sitagliptin 100 mg
- DRUG TTP399 400 mg
- DRUG TTP399 800 mg
Study Locations (20)
California
- - Canoga Park
- - Huntington Park
- - Los Angeles
- - West Hills
Texas
- - San Antonio
- - San Antonio
- - Schertz
Arizona
- - Mesa
- - Tuscon
Colorado
- - Centennial
- - Littleton
Connecticut
- - Waterbury
Florida
- - West Palm Beach
Illinois
- - Gurnee
Indiana
- - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02405260
The ClinicalTrials.gov registry entry for NCT02405260 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (96% lower). The listed sponsor is vTv Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02405260 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT02405260 about?
NCT02405260 is a clinical study titled "Add Glucokinase Activator to Target A1c". This trial is a multi-center, adaptive, randomized, double-blind, placebo- and active- controlled, parallel group, Phase 2 study in subjects with T2DM to evaluate the effect of TTP399 on HbA1c following administration for 6 months.
What is the current status of trial NCT02405260?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 2015-03. Estimated completion is 2016-09.
What conditions does trial NCT02405260 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT02405260?
The interventions under investigation include: Placebo (DRUG), Sitagliptin 100 mg (DRUG), TTP399 400 mg (DRUG), TTP399 800 mg (DRUG).
Who is sponsoring clinical trial NCT02405260?
This trial is sponsored by vTv Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02405260 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RECRUITING · Phase 2
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.